Compare · ARGX vs COEP
ARGX vs COEP
Side-by-side comparison of argenx SE (ARGX) and Coeptis Therapeutics Holdings Inc. (COEP): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and COEP operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $52.99B, about 519.2x COEP ($102.1M).
- Over the past year, ARGX is up 23.7% and COEP is up 42.7% - COEP leads by 19.1 points.
- ARGX has been more active in the news (8 items in the past 4 weeks vs 2 for COEP).
- ARGX has more recent analyst coverage (25 ratings vs 0 for COEP).
- Company
- argenx SE
- Coeptis Therapeutics Holdings Inc.
- Price
- $853.24-2.23%
- $16.27+0.81%
- Market cap
- $52.99B
- $102.1M
- 1M return
- -6.18%
- +46.05%
- 1Y return
- +23.67%
- +42.72%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2020
- News (4w)
- 8
- 2
- Recent ratings
- 25
- 0
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Latest ARGX
- SEC Form SC TO-C filed by argenx SE
- SEC Form SC TO-C filed by argenx SE
- SEC Form 6-K filed by argenx SE
- argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology Pipeline
- argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline
- SEC Form 6-K filed by argenx SE
- argenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business Update
- argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026
- SEC Form 6-K filed by argenx SE
- argenx to Host Autoimmune Myositis R&D Webinar
Latest COEP
- SEC Form POSASR filed by Coeptis Therapeutics Holdings Inc.
- Coeptis Therapeutics Holdings Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- Coeptis Therapeutics Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- Coeptis Therapeutics Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- SEC Form 3 filed by new insider Harris Jeffery Keeslar
- Coeptis Therapeutics Holdings Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Coeptis Therapeutics Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- SEC Form S-1 filed by Coeptis Therapeutics Holdings Inc.
- Coeptis Therapeutics Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form EFFECT filed by Coeptis Therapeutics Holdings Inc.